Doxycycline
- Generic Name
- Doxycycline
- Brand Names
- Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O8
- CAS Number
- 564-25-0
- Unique Ingredient Identifier
- 334895S862
- Background
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
- Indication
Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:
It is also used to treat infections caused by the following gram-negative microorganisms:
- Associated Conditions
- Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection
- Associated Therapies
- -
Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
- Conditions
- Cardiopulmonary BypassReperfusion InjuryCoronary Artery Bypass Grafting
- Interventions
- Drug: Placebo Oral TabletDrug: Periostat
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 56
- Registration Number
- NCT00246740
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
- Conditions
- AneurysmsArteriovenous Malformations
- Interventions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 26
- Registration Number
- NCT00243893
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens
- Conditions
- Abortion, InducedVomiting
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 40
- Registration Number
- NCT00177333
- Locations
- 🇺🇸
Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Medical Center Alkmaar
- Target Recruit Count
- 258
- Registration Number
- NCT00170222
- Locations
- 🇳🇱
Medisch centrum Alkmaar, Alkmaar, Noord-holland, Netherlands
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sorlandet Hospital HF
- Target Recruit Count
- 120
- Registration Number
- NCT00138801
- Locations
- 🇳🇴
Sørlandet Sykehus HF, Kristiansand, Vest-Agder, Norway
A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea
- Conditions
- Rosacea
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2005-08-19
- Lead Sponsor
- CollaGenex Pharmaceuticals
- Target Recruit Count
- 528
- Registration Number
- NCT00126399
Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair
- Conditions
- Aortic Aneurysm
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2010-03-04
- Lead Sponsor
- The Foundation for Barnes-Jewish Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00126204
- Locations
- 🇺🇸
Washington University School of Medicine / Barnes-Jewish Hospital, St. Louis, Missouri, United States
Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions
- Conditions
- Metastatic Cancer
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 480
- Registration Number
- NCT00002872
Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers
- Conditions
- PeriodontitisPeriodontal Diseases
- Interventions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- The Forsyth Institute
- Target Recruit Count
- 146
- Registration Number
- NCT00066066
- Locations
- 🇺🇸
Department of Periodontology, Cambridge, Massachusetts, United States
Norplant and Irregular Bleeding/Spotting
- Conditions
- Endometrial BleedingPeriodontal Disease
- First Posted Date
- 2003-07-15
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 50
- Registration Number
- NCT00064766
- Locations
- 🇺🇸
CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.